Wednesday, November 18, 2026

From Issue 106 (2026-11-18) · 16 stories in this issue

09 CAPITAL

❯ Isomorphic Labs raises $5 billion in Series C funding to move its first AI-designed drug candidates toward trials

Two rounds in six months, with funding now reaching clinical developmentAI drug developer Isomorphic Labs announced a $5 billion Series C on November 17, co-led by Greenoaks and Sequoia. New investors include a16z. Alphabet invested again alongside existing backers including Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. The company raised $2.1 billion in Series B funding in May.

The platform supports both owned and partnered programsDemis Hassabis founded the company in 2021. Its internal IsoDDE platform supports its own discovery teams and joint programs. The company advances some programs itself and brings its design capabilities into partners’ development plans for others. Both routes require staged validation before human trials.

The company reports positive preclinical resultsIn its financing announcement, Isomorphic Labs cited positive preclinical results in internal oncology and immunology programs and in partnered programs. This is the work done before studying candidates in people. The company wants to advance its first programs into trials, where safety and potential benefit can be assessed.

The $5 billion funds both platform and development capabilitiesThe company will keep investing in its design platform while building infrastructure to take candidates toward clinical development. At this stage, it needs the organizational capacity to manage further development and studies. The release lists models, drug programs and clinical infrastructure as uses of the proceeds.

▮ SIGNALOne use of the funding is to bring candidates to the stage where human data can test their value, allowing Isomorphic Labs to judge its platform in part by how its programs progress.